<DOC>
	<DOC>NCT01628926</DOC>
	<brief_summary>- To demonstrate the non-inferiority of SPM 962 to ropinirole in terms of efficacy in order to confirm clinical value of SPM 962. - To demonstrate the superiority of SPM 962 to placebo in terms of efficacy. - To investigate the tolerability and safety of SPM 962 up to 36.0 mg/day.</brief_summary>
	<brief_title>A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Subject diagnosed as having Parkinson's disease in accordance with "Diagnostic Criteria established by the Research Committee of MHLWspecified Intractable Neurodegenerative Diseases (1995)". Subject is 30 and more and less than 80 years of age at the time of informed consent. Hoehn &amp; Yahr stage 24 (on time). Total UPDRS Part 3 score is over 10 at screening test (on time). Subject is on a stable dose of Ldopa with no change in daily dose or dosing regimen for at least 28 days prior to the initial treatment of SPM 962. Subject has any of the following problematic symptoms; 1) Wearing off phenomenon (including frozen gait at off time and dystonia at off time) 2) On and off phenomenon 3) Delayedon and/or Noon phenomenon 4) Dyskinesia 5) Not well controlled with Ldopa. Subject who has previously participated in a clinical trial of SPM962 and taken the investigational product (IP). Subject has psychiatric symptoms, e.g. confusion, hallucination, delusion, excitation, delirium, abnormal behavior at screening test or baseline. Subject whose SBP declines by at least 30 mmHg from supine to standing position based on the orthostatic hypotension assessment, or subject who develops orthostatic hypotension at baseline. Subject has a history of epilepsy, convulsion and other. Subject who has complications or a history of serious cardiac diseases or arrhythmia (eg, congestive heart failure of class 3 or 4 in the NYHA classification, second or third degree atrioventricular block, complete left bundle branch block, sick sinus syndrome, ventricular fibrillation, myocardial infarction within 12 months prior to the screening test, or a complication of angina pectoris). Subjects has QTcinterval &gt;450 msec twice at screening. Subject has a the average QTcinterval from two ECGs &gt;450 msec in males and &gt;470 msec in females at baseline. Subject has congenital long QT syndrome. Subject whose serum potassium level is &lt; 3.5mEq/L at the screening test. Subject has a total bilirubin &gt;= 3.0 mg/dL or AST(GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or &gt;= 100 IU/L) at screening test, or suffers complications of active phase of chronic hepatitis or liver cirrhosis. Subject has BUN &gt;= 30 mg/dL or serum creatinine &gt;= 2.0 mg/dl at screening test. Subject has a history of allergic reaction to topical agents such as transdermal patch. Subject has a history of known intolerance/hypersensitivity to ropinirole and/or adverse drug reactions that prevent subject from receiving treatment. Subject is pregnant or nursing or woman who plans pregnancy during the trial. Subject is receiving therapy with prohibited drug specified in the study protocol. Subject has a history of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant. Subject has dementia, including DLB and PDD (MMSE score &lt;= 24 at screening). Subject who has a complication or history of malignant neoplastic disease, or received treatment for the disease within 12 months prior to the screening test. Subject is unable to give consent. Subject who is unable to properly record information in a diary. Subject is participating in another trial of IPs or received other IPs within 12 weeks prior to commencement of study treatment. Investigator judges that subject is inappropriate as a study subject with other reasons.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>